Reading CMV IgG Results: A Practical Interpretation Guide for IVD Professionals
Cytomegalovirus is one of the most common human herpesviruses. Infection is frequently silent in healthy adults, yet it can produce severe complications in newborns and in patients with weakened immunity. For laboratories and distributors, the interpretation logic behind CMV antibody testing matters as much as the assay itself: the same IgG result carries different weight depending on the patient group and the clinical question being asked.
What CMV IgG Actually Measures
Immunoglobulin G antibodies appear after the immune system has encountered the virus and generally persist for life. Their presence therefore signals previous exposure rather than an active, ongoing infection. In practice, CMV IgG testing answers one question well: has this person been infected before?
That answer is clinically relevant across several populations. For pregnant women, IgG status establishes whether a primary infection during gestation is possible. For transplant recipients, it helps predict reactivation risk. For immunocompromised patients undergoing chemotherapy or living with HIV/AIDS, serostatus guides monitoring intensity.
Most rapid formats used in routine screening combine IgG and IgM detection in a single device, giving laboratories both serostatus and a marker of recency from one specimen.
Positive IgG: Evidence of Prior Exposure
A positive IgG result indicates that the patient has been infected at some point and has mounted an immune response. It does not, on its own, indicate that the virus is currently replicating.
Two clinical situations make a positive result meaningful:
- Transplant planning. Seropositive donor or recipient status raises the probability of reactivation, which can influence decisions about antiviral prophylaxis and post-transplant monitoring schedules.
- Immunosuppression management. In patients with compromised cellular immunity, latent CMV may reactivate, so a positive baseline result sets the reference point for future surveillance.
Negative IgG: A Susceptible Patient
A negative result means no detectable IgG antibodies, which usually reflects never having been infected. Such individuals have no immunity and remain susceptible to a primary infection.
This finding carries particular weight in obstetric care. A seronegative pregnant woman who acquires CMV for the first time during pregnancy faces a higher risk of transmitting the virus to the fetus compared with women infected before conception. The same logic applies in occupational settings with frequent exposure, such as hospitals and childcare centers, where seronegative staff benefit from hygiene-based preventive measures.
Equivocal Results: Handling the Grey Zone
Borderline signals that fall between the assay's cut-off values are reported as equivocal. They may result from very early seroconversion, waning antibody levels, biological variation, or assay characteristics near the threshold.
Standard practice is to resolve them rather than report them as definitive. Typical approaches include:
- Retesting the same sample or a fresh specimen within approximately two weeks.
- Running an IgM assay in parallel to check for recent seroconversion.
- Applying an IgG avidity assay when timing of infection is the key question.
Clear documentation of equivocal outcomes and follow-up actions is important for laboratories working under quality-management requirements.
The Role of IgM in Establishing Timing
IgM antibodies are the first to appear after infection and are generally associated with recent exposure. When an IgM result is positive alongside a positive IgG, clinicians consider recent infection or reactivation; IgM alone may indicate a very early phase before IgG has developed.
Because IgM can sometimes persist or reappear without new infection, it is best read together with IgG rather than in isolation. Dual-parameter rapid tests simplify this workflow by delivering both results from a single run.
IgG Avidity: Narrowing the Infection Window
The avidity test measures how firmly IgG antibodies bind to viral antigens. Avidity matures over time after the initial immune response.
- High avidity is consistent with infection in the more distant past.
- Low avidity points toward infection within roughly the last four months.
For a seroconverting pregnant patient, this distinction is critical: a high-avidity result at first presentation generally argues against a recent primary infection, while a low-avidity result supports one and may warrant further investigation.
Combining Results into an Interpretation Framework
| IgG | IgM | Typical interpretation |
|---|---|---|
| Positive | Negative | Past infection, established immunity |
| Positive | Positive | Recent infection or reactivation; confirm with avidity |
| Negative | Negative | No evidence of previous infection; patient susceptible |
| Negative | Positive | Very early infection; repeat testing recommended |
| Equivocal | Any | Retest and consider avidity testing |
Factors That Affect Result Reliability
Interpretation depends on assay performance as much as on clinical context. Sensitivity and specificity near the cut-off, specimen handling, and patient-related biological variation can all shift a result. Working with manufacturers that apply consistent quality control across production batches reduces avoidable variability — a relevant consideration for distributors supplying multiple markets.
Practical Takeaways for Buyers and Laboratories
- Confirm that the kit format covers both IgG and IgM if dual interpretation is required.
- Check the instructions for equivocal handling and retest guidance before validation.
- Pair rapid screening with avidity testing capability when serving obstetric or transplant accounts.
- Align labeling and documentation with the regulatory requirements of your destination market.
FAQ
Does a positive CMV IgG result mean the patient is contagious?
No. IgG indicates previous exposure and immune response, not active viral shedding. Reactivation and contagiousness are separate questions that require clinical assessment and, where appropriate, viral DNA testing.
Why should an equivocal result not be reported as negative?
A borderline value may reflect early seroconversion or levels close to the assay cut-off. Reporting it as negative could incorrectly classify a susceptible or recently infected patient, so retesting or supplementary testing is recommended.
How does avidity testing help in prenatal screening?
Avidity indicates how long ago the infection occurred. High avidity generally excludes a recent primary infection within about four months, while low avidity supports one — information that directly shapes follow-up decisions during pregnancy.